Drug Type Small molecule drug |
Synonyms Gusacitinib (USAN/INN), Gusacitinib Hydrochloride, ASN-002 + [3] |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H28N8O2 |
InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-N |
CAS Registry1425381-60-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eczema, Dyshidrotic | Phase 3 | United States | - | |
Chronic dermatitis | Phase 2 | United States | 03 Jan 2019 | |
Chronic dermatitis | Phase 2 | Canada | 03 Jan 2019 | |
Chronic eczema | Phase 2 | United States | 03 Jan 2019 | |
Chronic eczema | Phase 2 | Canada | 03 Jan 2019 | |
Moderate Atopic Dermatitis | Phase 2 | United States | 05 Jul 2018 | |
Moderate Atopic Dermatitis | Phase 2 | Canada | 05 Jul 2018 | |
Moderate Atopic Dermatitis | Phase 2 | Germany | 05 Jul 2018 | |
Severe Atopic Dermatitis | Phase 2 | United States | 05 Jul 2018 | |
Severe Atopic Dermatitis | Phase 2 | Canada | 05 Jul 2018 |
Phase 2 | 162 | (ASN002 40 mg) | qbrzaltthf(lshbnpyoij) = jcbkifgiav tebihusmxm (sfpvtvceeb, 12.914) View more | - | 18 Sep 2023 | ||
(ASN002 60 mg) | qbrzaltthf(lshbnpyoij) = ehzpfxfhie tebihusmxm (sfpvtvceeb, 7.687) View more | ||||||
Phase 1/2 | 51 | (10 mg BID) | sksvdzvnun = daapfvpfyr gzukfvbqev (mfxudzrgtu, cijgpvkqns - oxgsdsvjww) View more | - | 07 Jun 2023 | ||
(20 mg BID) | sksvdzvnun = nmiotokhmm gzukfvbqev (mfxudzrgtu, tohivxctoe - rpkidodefk) View more | ||||||
Phase 2 | 97 | (ASN002 40 mg) | kwfhgrpkco(oicwhykkcu) = ciyvpswmhr pktutscpvs (kfxmxxgxht, 40.65) View more | - | 09 May 2023 | ||
(ASN002 80 mg) | kwfhgrpkco(oicwhykkcu) = snhzgjrsay pktutscpvs (kfxmxxgxht, 26.97) View more | ||||||
Phase 2 | 244 | (ASN002 40 mg) | airthdujxf(txngudycwb) = yybknyvxyc jyioppjmfj (lklwfekaqi, 10.88) View more | - | 15 Nov 2022 | ||
(ASN002 60 mg) | airthdujxf(txngudycwb) = onxjcbmbqj jyioppjmfj (lklwfekaqi, 9.82) View more |